Inactive Instrument

RLS Global AB (publ)

RLS

SE0005190725

RLS Global AB Receives its First Order from ConvaTec

November 19, 2021 at 02:30 am

RLS Global AB (publ) received its first order from ConvaTec. As of January 1, 2022, ConvaTec will take ownership of the commercial process for ChloraSolv in Europe. The launch of ChloraSolv will take place in various stages with focus during 2022 in the Nordic countries, the Netherlands, the United Kingdom, Germany and France.

Latest news about RLS Global AB (publ)

RLS Global to Submit Bankruptcy Application	11-20	MT
RLS Global Abandons ChloraSolv Partnership with ConvaTec Group	11-10	MT
RLS Global Launches Strategic Review of Options for ChloraSolv Commercialization	11-10	MT
RLS Global Initiates Strategic Review Process Aiming to Commercialize ChloraSolv	11-09	CI
RLS Global and Convatec Agree to Terminate Collaboration Agreement	11-09	CI
RLS Global Enrols First Patient in Clinical Trial on Pressure Ulcers	23-09-06	MT
RLS Global AB Announces First Patient Included in New Clinical Investigation on Pressure Ulcers	23-09-06	CI
RLS Global AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-25	CI
RLS Global Receives SEK5 Million Loan	23-08-25	MT
RLS Global Names New CFO	23-08-22	MT
RLS Global AB Announces Chief Financial Officer Changes	23-08-22	CI
Cereno Scientific Names RLS Global CFO to Same Role	23-08-21	MT
RLS Global AB Auditor Raises 'Going Concern' Doubt	23-06-08	CI
RLS Global AB Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-31	CI
RLS Global AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022	23-02-28	CI
RLS Global Chairman to Depart in February; Successor Nominated	23-01-25	MT
Steve Krognes to Step Down as Chairman	23-01-24	CI
RLS Global AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-24	CI
RLS Global To Issue New Shares To Pay Off Loan From Zebra Holdings	22-09-23	MT
RLS Global AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-26	CI
RLS Global Names Observe Medical Exec As New CEO	22-08-23	MT
RLS Global AB Introduces Chlorasolv in the Veterinary Care Segment in Scandinavia	22-06-01	CI
Swedish Pharmaceutical Group RLS Global Taps Local Distributor In Middle East	22-05-30	MT
RLS Global AB Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-11	CI
RLS Global CEO Resigns	22-04-04	MT

Chart RLS Global AB (publ)

Duration

Period

More charts

Company Profile

RLS Global AB, formerly OraSolv Products AB, is a Sweden-based company engaged in the development of dental care products. It is primarily engaged in the development of biochemical products and methods for minimally invasive dentistry. The Company's product portfolio includes Carisolv, a biochemical method for the removal of caries; Perisolv, product for the treatment of periodontitis; ChloraSolv, a treatment that cleanses and heals chronic wounds and Kindersolv, a caries treatment for children. The Company manufactures its products in the Sahlgrenska Science Park and sells them through distributors worldwide. The Company's main shareholders are Rls Global Intressenter AB, Joki Invest AB, Zebra Holdings and Investments Limited.

Sector

Pharmaceuticals

Calendar

2024-08-22 - Q2 2024 Earnings Release (Projected)

More about the company

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ELI LILLY AND COMPANY	+40.73%	739B
NOVO NORDISK A/S	+32.83%	598B
JOHNSON & JOHNSON	-6.30%	353B
MERCK & CO., INC.	+15.15%	318B
ABBVIE INC.	+4.05%	285B
ASTRAZENECA PLC	+15.00%	240B
NOVARTIS AG	+9.78%	210B
ROCHE HOLDING AG	-5.52%	206B
AMGEN INC.	+6.17%	164B

Other Pharmaceuticals